Key Highlights
- CVS slid in a second straight day of retreat across health insurers.
- CMS proposed a rule Monday to expand Medicare Advantage audits.
- Humana finished as the S&P 500's worst performer on the day.
- The Fed's December meeting looms after hawkish minutes released Wednesday.
Caught in the insurer selloff
CVS Health (NYSE:CVS) slid during Wednesday's session, joining a broad retreat in Health Insurance stocks for a second straight day. The pressure stemmed from a proposed rule by the Centers for Medicare & Medicaid Services, released Monday, that would expand audits of Medicare Advantage plans.
Humana (NYSE:HUM) finished as the S&P 500's worst performer, while UnitedHealth Group (NYSE:UNH) was the biggest drag on the Dow Jones Industrial Average. Elevance Health (NYSE:ELV), Centene (NYSE:CNC), Cigna (NYSE:CI) and Molina Healthcare (NYSE:MOH) also fell sharply. Health care was the second-worst sector in the S&P 500, and its decline pushed the Dow to its session low.
The Dow closed down 561.25 points at 50,198.17, while the S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss.
Why CVS is exposed
CVS is often thought of as a pharmacy chain, but it is also one of the country's largest health insurers through Aetna. Aetna offers Medicare Advantage plans to millions of seniors, along with employer and individual coverage. CVS also owns Caremark, one of the largest pharmacy benefit managers, along with its retail pharmacies and health care services.
That structure means the Medicare Advantage proposal hits one important part of the company rather than the whole. Medicare Advantage insurers are paid more for members with more serious health conditions, based on reported diagnoses, and audits check whether those diagnoses are supported by medical records.
Sen. Elizabeth Warren wrote on X that UnitedHealth, CVS and Cigna "each own a health insurer, pharmacy middleman, and pharmacy" and "take a cut at every step."
The CRUSH rule in brief
The proposal, called Comprehensive Regulations to Uncover Suspicious Healthcare, or CRUSH, would let CMS extrapolate findings from risk adjustment data validation audits, or RADV audits, from a sample of records to an entire contract, starting with payment year 2018. CMS estimates it could save about $90 billion over 10 years.
CMS Administrator Dr. Mehmet Oz framed the proposal as a way to "crush fraud, waste, and abuse." The rule sets audit methods for the program as a whole and does not single out CVS or any other insurer. It is a proposal, not a final rule, and comments are due January 19, 2027.
It also revives a 2023 RADV rule that a Texas federal judge vacated in September 2025 in a case brought by Humana.
Analysts expect a fight
One analyst said that "The substantially larger collection estimate reflects broader auditing," and that CMS "could choose to make adjustments in the final rule." Oppenheimer expects legal challenges and believes plans would price the cost into their bids.
That suggests the longer-term effect could show up in how insurers design Medicare Advantage benefits and premiums for future years, as well as in any direct repayments.
Why Aetna Keeps CVS in the Audit Debate
The comment period, which runs through January 19, 2027, is the next step, and CMS could change the rule before finalizing it. Investors will watch for any statements from CVS on how the proposal might affect Aetna's Medicare business.
UnitedHealth's 2027 outlook, expected before year-end, could offer the first detailed industry signal on planning assumptions. Beyond health care, the Federal Reserve's December 8 to 9 meeting looms after hawkish minutes released Wednesday, and Walmart (NASDAQ:WMT), a rival in retail pharmacy, reports Earnings before Thursday's open.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...